AlphAIalphai — Financial news for AI agents
investing.comSEP 22 min read$REGN

Regeneron Pharmaceuticals stock hits 52-week high at $847.60

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

Original reporting
investing.com
Published Sep 2, 2026, 4:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

Earnings beat and raised price targets suggest short‑term upside, but valuation concerns persist.

02

Market read

Strong earnings and analyst upgrades make REGN a notable mover in the healthcare sector today.

03

What to watch

Potential headwinds from competition and regulatory scrutiny not discussed.

Relevance 8/10Novelty 8/10Timing: same-day earnings release

Background

Regeneron hit a 52‑week high and posted robust Q2 earnings, prompting analyst upgrades.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron reported Q2 2026 results with $14.29 EPS and $4.29B revenue, beating expectations.

Expected impact

upward bias in short term

Evidence & confidence

Earnings beat, revenue growth, and raised price targets indicate positive momentum.

Market effects

Sector

Biotech sector may benefit from Regeneron's strong performance.

Regional

U.S. markets likely see modest uplift in healthcare stocks.

Global

Limited to biotech investors worldwide.

Counterpoint

What could challenge this read

Valuation remains high; price may be stretched despite earnings beat.

Key entities

  • Company
    Regeneron Pharmaceuticals Inc.

    Biotech firm reporting Q2 2026 results.

  • Analyst
    BofA Securities

    Raised price target to $891.

  • Analyst
    Bernstein SocGen Group

    Raised price target to $756.

Read at source← All news

Related articles

SEP 3
$REGNLowAI 8/10

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit over alleged misrepresentations regarding a Phase 3 clinical trial for a melanoma treatment. The trial's failure caused a $11B market cap drop, prompting the lawsuit. Investors who bought shares between Aug. 1, 2025, and May 15, 2026, may be affected. The firm Hagens Berman is investigating.

prnewswire.com2 min
AUG 31
$REGNMedAI 8/10

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

simplywall.st3 min
AUG 29
$REGNMedAI 9/10

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

yahoo.com2 min
AUG 28
$REGNHighAI 9/10

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit after a Phase 3 clinical trial for a melanoma treatment failed, causing a $11B market cap wipeout. The lawsuit alleges Regeneron misled investors about the trial's prospects between August 2025 and May 2026. Investors with losses before the September 2026 deadline are urged to contact Hagens Berman.

prnewswire.com2 min
AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 27
$REGNHighAI 8/10

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study.

accessnewswire.com1 min